Recent News

Daratumumab-Based Combination Therapy for Newly Diagnosed Multiple Myeloma

Phase I Trial Results With Immunotherapy bb21217 for Resistant Multiple Myeloma

Dana-Farber Receives $16.5 Million Gift to Support Multiple Myeloma Research

Combination Therapy for Frail and Unfit Patients Newly Diagnosed With Multiple Myeloma

Belantamab Mafodotin Granted Priority Review by FDA for Resistant Multiple Myeloma

Dual-Target CAR T-Cell Therapy in Resistant Multiple Myeloma

Venetoclax in Combination With Dexamethasone for Resistant Multiple Myeloma

Novel Monoclonal Antibody in Relapsed or Refractory Multiple Myeloma

Ixazomib-Based Combination for High-Risk Smoldering Multiple Myeloma

Is Ixazomib/Dexamethasone a New Option for Treating AL Amyloidosis?

ASH 2019: Dose-Finding Study of Novel Immunotherapy for Resistant Myeloma

ASH 2019: Early Trial Results With CAR T-Cell Therapy for Resistant Myeloma

ASH 2019: Characterizing Molecular Drivers of Myeloma Cells Via CRISPR Activation

ASH 2019: Addition of Selinexor to Treatment Regimen for Resistant Myeloma

ASH 2019: CANDOR Trial of Daratumumab Combination Therapy for Resistant Myeloma

ASH 2019: Early Results With Multiplexed Genetic Engineering in Treating Multiple Myeloma

STORM Trial: Oral Selinexor Combination in Refractory Myeloma

Carfilzomib-Based Therapy for Transplant-Eligible Patients With Myeloma

Transitioning From Bortezomib to Ixazomib in Multiple Myeloma

Daratumumab Plus Triplet Therapy for Transplant-Eligible Patients With Multiple Myeloma

Combination Therapy With Venetoclax in Resistant Multiple Myeloma

Early-Phase Trial of New Monoclonal Antibody Plus Pembrolizumab in Resistant Myeloma

Comparison of First-Line Treatments in Older Patients With Myeloma

Melflufen-Based Combination Therapy for Resistant Myeloma

Combination Therapy With Selinexor, Lenalidomide, and Dexamethasone in Resistant Myeloma

Orphan Drug Designation Granted to Immunotherapy for Multiple Myeloma

ESMO 2019: First-Line Versus Non–First-Line Bortezomib in Asian Patients With Myeloma

IMW 2019: Bortezomib-Based Regimens in Newly Diagnosed Multiple Myeloma

SOHO 2019: Are Real-World and Clinical Data Synchronized With Treatment of Resistant Myeloma?

Daratumumab Combination Approved for Transplant-Eligible Patients With Multiple Myeloma

SOHO 2019: Is Minimal Residual Disease Testing Ready for Prime Time?

IMW 2019: Daratumumab-Based Therapy Improves Response in Newly Diagnosed Myeloma

SOHO 2019: Update on the Future of Induction Therapy in Multiple Myeloma

Pilot Study of Ixazomib Plus Dexamethasone in High-Risk Smoldering Myeloma

Quality Care 2019: Program Hastens Start of Bone-Modifying Agents in Myeloma

Assessing Risk of Immunomodulatory Drug–Related Blood Clots in Patients With Multiple Myeloma